Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18127922 | 0.81 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3PDE4A | |
| SCHEMBL9122677 | 0.81 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3PDE4A | |
| SCHEMBL8947982 | 0.79 | POLB (0.40) | ADORA2BADORA2AADORA1ADORA3CYP3A4 | |
| SCHEMBL11072744 | 0.79 | ADORA2B (0.51) | ADORA2BADORA2AADORA1PDE4APDE4B | |
| SCHEMBL5272642 | 0.75 | CYP2C19 (0.48) | ADORA2BADORA2AADORA1CYP3A4 | |
| SCHEMBL11409326 | 0.75 | POLB (0.50) | ADORA2BADORA2AADORA1CYP3A4 | |
| SCHEMBL4543814 | 0.75 | POLB (0.64) | CYP3A4 | |
| SCHEMBL10818058 | 0.75 | ALDH1A1 (0.38) | ADORA2BADORA1CYP3A4 | |
| SCHEMBL3435824 | 0.74 | ADORA2B (0.80) | ADORA2BADORA2AADORA1ADORA3CYP3A4 | |
| SCHEMBL10629155 | 0.74 | ADORA1 (0.67) | ADORA2BADORA2AADORA1ADORA3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815446-B1 | ADMINISTERING 8-AMINO-XANTHINE DERIVATIVE AS ANTIASTHMATIC OR ANTIDIARRHEA AGENT | VANDERBILT UNIVERSITY | 2004-11-09 | — | — | US | disclosed |
| US-6806270-B2 | XANTHINE DERIVATIVES, SUCH AS 3-ISOBUTYL-8-PYRROLIDINYLXANTHINE; TREATING ASTHMA, DIARRHEA, ETC. | VANDERBILT UNIVERSITY | 2004-10-19 | — | — | US | disclosed |
| US-20030087904-A1 | Selective antagonists of A2B adenosine receptors | VANDERBILT UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| EP-1208100-B1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | UNIV VANDERBILT (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1208100-A1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | VANDERBILT UNIVERSITY (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016134-A1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | VANDERBILT UNIVERSITY (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0407651-A2 | Use of 1,3-diisobutyl-8-methylxanthine as a bronchodilator and antiallergy agent | J. URIACH & CIA. S.A. (ES) | 1991-01-16 | — | — | EP | disclosed |
| US-4644001-A | BRONCHODILATOR, CARDIOTONIC AGENTS | AKTIEBOLAGET DRACO (SE) | 1987-02-17 | — | — | US | disclosed |
| US-4548818-A | Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines | AKTEBOLAGET DRACO, A COMPANY OF SWEDEN (SE) | 1985-10-22 | — | — | US | disclosed |
| US-4546182-A | TREATMENT OF RESPIRATORY AND CARDIO-VASCULAR DISORDERS | AKTIEBOLAGET DRACO (SE) | 1985-10-08 | — | — | US | disclosed |
| US-4120947-A | Xanthine compounds and method of treating bronchospastic and allergic diseases | COOPER LABORATORIES, INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4089959-A | Long-acting xanthine bronchodilators and antiallergy agents | COOPER LABORATORIES, INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087904-A1 | Selective antagonists of A2B adenosine receptors | ADORA2B, ADORA1, ADORA2A | ADORA2B 1/4885ADORA2A 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.